Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 460.00
Bid: 440.00
Ask: 480.00
Change: -15.00 (-3.19%)
Spread: 40.00 (9.09%)
Open: 460.00
High: 470.00
Low: 455.00
Yest. Close: 470.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Faron Pharma requests arbitration over Traumakine manufacturing deal

Mon, 30th Dec 2019 15:39

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.
The AIM-traded firm said it had concluded that it considered the letter in which Rentschler Biopharma stated that it was terminating the agreement concerning the API manufacturing process for Traumakine to be "without merit and in breach of the underlying agreement" between the parties.

Faron said it also considered Rentschler to have otherwise breached the agreement.

"As a remedy, the company has filed a request for arbitration with the Arbitration Institute of the Stockholm Chamber of Commerce seeking damages," the board said in its statement.

"To fund the proceedings, the company has entered into a litigation funding agreement with a third-party recovery services provider offering non-recourse financing which, subject to final quantum, is expected to cover both the company's legal expenses and the adverse party costs.

"The funder would receive a typical portion of any damages awarded in the event of success."

Faron Pharma said further updates would be provided in due course, as and when appropriate.

At 1532 GMT, shares in Faron Pharmaceuticals were down 2.75% at 265.5p.

More News

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

20 Mar 20 11:25

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

20 Mar 20 10:49

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

13 Mar 20 16:04

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

9 Mar 20 14:07

Faron gets FDA tick from proposed design of next 'Traumakine' study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.

9 Mar 20 10:26

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

5 Mar 20 14:28

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

2 Mar 20 12:04

Faron Pharmaceuticals acquires rights to AOC3 inhibitors

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application.

2 Mar 20 10:08

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

6 Feb 20 14:17

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

27 Jan 20 11:22

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

13 Jan 20 11:54

Faron Pharma requests arbitration over Traumakine manufacturing deal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.

30 Dec 19 15:39

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

30 Dec 19 10:56

Faron Pharmaceuticals upbeat on new data from 'MATINS' study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.

11 Dec 19 13:42

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

11 Dec 19 10:45

Login to your account

Don't have an account? Click here to register.